Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Feature|Videos|August 13, 2025
Advances across urology: Insights from UNC faculty
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Urologists from the University of North Carolina share insights into key advancements across the field of urologic oncology.
Advertisement
The field of urologic oncology is rapidly evolving. Urology Times® recently spoke with several urologists from the University of North Carolina, who shared insights into key advancements across the field.
Specifically, you'll hear from:
- Marc A. Bjurlin, DO, MSc, FACOS on the evolving role of mpMRI
- Kathryn H. Gessner, MD, PhD on the growing applications for genomic testing
- Mary Beth Westerman, MD on the amendment to microhematuria guideline
- Zachary Feuer, MD on a rapid access program for elevated PSA
Advertisement
Related to this article
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
3
How PSMA-PET shapes staging and recurrence workup in prostate cancer
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5